Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Marie L., Haynes, Laura, Parker, Chris, Iversen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283534/
https://www.ncbi.nlm.nih.gov/pubmed/22232132
http://dx.doi.org/10.1093/jnci/djr514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283534/
https://www.ncbi.nlm.nih.gov/pubmed/22232132
http://dx.doi.org/10.1093/jnci/djr514

Ejemplares similares